PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
Status:
Completed
Trial end date:
2020-05-06
Target enrollment:
Participant gender:
Summary
The PIPAC nab-pac study is designed to examine the maximal tolerated dose of albumin bound
nanoparticle paclitaxel (nab-pac, Abraxane) administered with repeated pressurized
intraperitoneal aerosol chemotherapy (PIPAC), in a multicentre, multinational phase I trial.
Phase:
Phase 1
Details
Lead Sponsor:
University Hospital, Ghent
Collaborators:
Candiolo Cancer Institute - IRCCS Centre Hospitalier Universitaire Vaudois Hopital Lariboisière Kom Op Tegen Kanker University Ghent University Women's Hospital Tübingen